Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study

References

• Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. doi:10.1016/s0140-6736(01)05701-4
   PubMed Web of Science ®Google Scholar
• Akhtar T, Bandyopadhyay D, Ghosh RK, Aronow WS, Lavie CJ, Yadav N. Advances in the pharmacogenomics of antiplatelet therapy. Am J Ther. 2020;27(5):e477–e484. doi:10.1097/mjt.0000000000001013
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–2913. doi:10.1161/01.Cir.0000072771.11429.83
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251. doi:10.1016/j.jacc.2004.09.067
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259–274. doi:10.1111/j.1755-5922.2009.00096.x
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi:10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036–1045. doi:10.1016/j.jacc.2015.06.1323
   PubMed Web of Science ®Google Scholar
• Aronow WS. Approach to symptomatic coronary disease in the elderly: TIME to change? Lancet. 2001;358(9286):945–956. doi:10.1016/s0140-6736(01)06111-6
   PubMed Web of Science ®Google Scholar
• Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708–713. doi:10.1001/jama.286.6.708
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–2747. doi:10.1161/CIRCULATIONAHA.110.009449
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Thrombolysis. 2005;3(4):692–694. doi:10.1111/j.1538-7836.2005.01204.x
   Web of Science ®Google Scholar
• Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200–1206. doi:10.1016/j.amjcard.2005.06.056
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5(5):680–688. doi:10.1161/CIRCOUTCOMES.111.964395
   PubMed Web of Science ®Google Scholar
• Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2549–2569. doi:10.1161/CIRCULATIONAHA.107.182615
   PubMed Web of Science ®Google Scholar
• Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2570–2589. doi:10.1161/CIRCULATIONAHA.107.182616
   PubMed Web of Science ®Google Scholar
• Dai X, Busby-Whitehead J, Alexander KP. Acute coronary syndrome in the older adults. J Geriatr Cardiol. 2016;13(2):101–108. doi:10.11909/j.issn.1671-5411.2016.02.012
   PubMedGoogle Scholar
• Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. The Lancet. 2020;395(10233):1374–1381. doi:10.1016/s0140-6736(20)30325-1
   PubMed Web of Science ®Google Scholar
• Schmucker J, Fach A, Mata Marin LA, et al. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions. J Am Heart Assoc. 2019;8(18):e012530. doi:10.1161/JAHA.119.012530
   PubMed Web of Science ®Google Scholar
• Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation. 2020;142(18):1700–1708. doi:10.1161/circulationaha.120.050645
   PubMed Web of Science ®Google Scholar
• Bianco M, Careggio A, Biole CA, et al. Ticagrelor or clopidogrel after an acute coronary syndrome in the elderly: a propensity score matching analysis from 16,653 patients treated with PCI included in two large multinational registries. Cardiovasc Drugs Ther. 2021;35(6):1171–1182. doi:10.1007/s10557-021-07213-y
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–261. doi:10.1161/CIRCULATIONAHA.119.040167
   PubMed Web of Science ®Google Scholar
• Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015;169(6):899–905 e1. doi:10.1016/j.ahj.2015.03.015
   PubMed Web of Science ®Google Scholar
• Marquis-Gravel G, Dalgaard F, Jones AD, et al. Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI. J Am Coll Cardiol. 2020;76(2):162–171. doi:10.1016/j.jacc.2020.05.031
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubin S, Abu-Assi E, Munoz-Pousa I, et al. Usefulness of bleeding after acute coronary syndromes for unmasking silent cancer. Am J Cardiol. 2020;125(12):1801–1808. doi:10.1016/j.amjcard.2020.03.023
   PubMed Web of Science ®Google Scholar
• Verdoia M, Pergolini P, Rolla R, et al. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. J Thromb Thrombolysis. 2016;14(1):57–64. doi:10.1111/jth.13177
   Web of Science ®Google Scholar